Advances in LAG3 cancer immunotherapeutics

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has revolutionized cancer treatment, improving progression-free survival (PFS) and overall survival (OS).
• Lymphocyte-activation gene 3 (LAG3) is an inhibitory receptor targeted in cancer immunotherapy.
• Combination therapy, such as LAG3 and PD1 blockade, is emerging as a key strategy.

Purpose of the Study:

• To review the role of LAG3 in regulating antitumor immunity.
• To discuss the clinical evaluation of LAG3 inhibition in cancer treatment.
• To highlight the development of novel LAG3-directed biologics and bispecific antibodies.

Main Methods:

• Literature review of preclinical and clinical studies on LAG3 inhibition.
• Analysis of current clinical trial data for LAG3-targeted therapies.
• Discussion of emerging therapeutic strategies involving bispecific antibodies targeting multiple inhibitory receptors on T cells.

Main Results:

• LAG3 inhibition, especially in combination with PD1 blockade, has demonstrated significant therapeutic potential in advanced melanoma.
• New LAG3-directed biologics are under active clinical investigation.
• Bispecific antibodies targeting multiple inhibitory receptors on exhausted T cells are being evaluated.

Conclusions:

• LAG3 plays a critical role in modulating the immune response against cancer.
• Combination strategies involving LAG3 inhibition represent a promising frontier in cancer immunotherapy.
• Ongoing clinical trials are crucial for establishing the efficacy and safety of LAG3-targeted therapies across various cancers.